| Kumar A, India, 2011 |
Cohort study |
2009-2010 |
Burn ward of Guru Teg Bahadur Hospital |
Sepsis/septicemia |
80 |
28 |
8 |
1 |
7 |
Cephalexin (62.5%), erythromycin (62.5%), amoxicillin (62.5%), ciprofloxacin (62.5%), cefoxitin (87.5%), co-trimoxazole (75%), gentamicin (50%) |
Vancomycin (100%) |
7 |
| Perween N, India, 2015 |
Cross-sectional study |
2012 |
Burn ward of a tertiary care hospital |
Burn wound infection |
1294 |
883 |
141 |
61 |
80 |
Penicillin (100%), cephalexin (100%), cefazolin (100%), erythromycin (98.7%), clindamycin (97.4%), gentamicin (97.4%), amikacin (84.6%), ofloxacin (96.2%), ciprofloxacin (100%) |
Vancomycin (100%), teicoplanin (100%), linezolid (97.4%), chloramphenicol (85.9%), rifampicin (88.5%) |
6 |
| Amissah NA, Ghana, 2017 |
Cross-sectional study |
2014-2015 |
Burn unit, Reconstructive Plastic Surgery and Burn Center of Korle Bu Teaching Hospital |
Nosocomial infections/burn wound infection |
62 |
80 |
80 |
58 |
22 |
N/A |
N/A |
7 |
| Fu Y, China, 2012 |
Cross-sectional study |
1998-2009 |
Burn center, Changhai Hospital |
Burn wound infection |
114 |
3620 |
1382 |
229 |
1153 |
N/A |
Vancomycin (100%) |
7 |
| Taneja N, India, 2004 |
Cohort study |
2000-2001 |
Burn unit of a tertiary care referral center |
Hospital-acquired infections/burn wound infection |
74 |
85 |
30 |
15 |
15 |
Erythromycin (66.6%), netilmicin (22.2%), cefotaxime (55.5%), ciprofloxacin (44.4%), gentamicin (77.7%) |
N/A |
8 |
| Ekrami A, Iran, 2015 |
Cross-sectional study |
2013-2014 |
Burn center, Taleghani burn hospital |
Burn wound infection |
N/A |
103 |
96 |
34 |
50 |
Penicillin (100%), cefoxitin (93%), ampicillin (89%), erythromycin (71%), tetracycline (75%), gentamicin (64%), ciprofloxacin (71%), ampicillin-sulbactam (57%), ceftazidime (79%) |
N/A |
7 |
| Cen H, China, 2015 |
Cross-sectional study |
2011-2013 |
Burn ward of Zhejiang University of Medicine |
Hospital-acquired infections/burn wound infection |
1942 |
2212 |
410 |
N/A |
324 |
N/A |
N/A |
6 |
| Qader AR, Iraq, 2010 |
Cross-sectional study |
2008-2009 |
Sulaimani Burn, Reconstructive and Plastic Surgery Hospital |
Nosocomial infections/burn wound infection |
760 |
1405 |
462 |
202 |
179 |
N/A |
N/A |
7 |
| Bunnell KL, USA, 2017 |
Cohort study |
2012-2015 |
Trauma and burn ICU at Rhode Island Hospital, a level I trauma center |
Nosocomial infections |
80 |
115 |
N/A |
87 |
13 |
N/A |
N/A |
6 |
| Gang RK, Kuwait, 2000 |
Cohort study |
1992-1998 |
Burn Unit of the Al-Babtain Centre for Burns and Plastic Surgery of the Ibn Sina Hospital |
Sepsis/septicemia |
80 |
91 |
N/A |
11 |
8 |
N/A |
N/A |
6 |
| DiMuzio EE, USA, 2012 |
Cross-sectional study |
2004-2011 |
Cincinnati Shriners Hospital for Children |
Burn wound infection |
N/A |
7217 |
1790 |
N/A |
806 |
N/A |
N/A |
8 |
| Raz-Pasteur A, Israel, 2012 |
Cross-sectional study |
2001-2009 |
Rambam Healthcare Campus (RHC) Burn Unit and ICU |
Sepsis |
159 |
159 |
N/A |
25 |
83 |
N/A |
N/A |
8 |
| Ronat J, Iraq, 2014 |
Cross-sectional study |
2008-2009 |
Sulaymaniyah burn center |
Systemic infections due to burns |
1169 |
65 |
17 |
N/A |
N/A |
Penicillin G (100%), oxacillin (100%), gentamicin (88%), fusidic acid (71%), levofloxacin (59%), clindamycin (35%), minocycline (29%), rifampin (29%) |
Quinupristin-dalfopristin (88%), nitrofurantoin (100%), vancomycin (100%) |
7 |
| Appelgren P, Sweden, 2002 19
|
Cohort study |
1993-1995 |
Burn unit of Karolinska Hospital |
Nosocomial/community acquired infections |
230 |
200 |
69 |
66 |
3 |
N/A |
N/A |
8 |
| Bang LR, Kuwait, 2004 |
Cohort study |
1992-2001 |
Burns Unit, Al-Babtain Centre for Burns and Plastic Surgery |
Sepsis/septicemia |
166 |
253 |
119 |
11 |
108 |
N/A |
N/A |
6 |
| Vostrugina K, Lithuania, 2006 |
Cohort study |
1999-2003 |
Department of Plastic Surgery and Burns of Kaunas University of Medicine Hospital |
|
82 |
82 |
N/A |
24 |
58 |
N/A |
N/A |
7 |
| Schweizer M, USA, 2012 |
Cohort study |
2009-2010 |
BTU of a teaching hospital with a level-1 trauma center |
Sepsis/bacteremia |
144 |
144 |
N/A |
N/A |
24 |
Erythromycin (91%) |
Linezolid (100%), daptomycin (100%), quinupristin-dalfopristin (100%), rifampin (100%), co-trimoxazole (100%), gentamicin (100%), vancomycin (100%) |
6 |
| Naqvi Z.A., Pakistan, 2007 |
Cross-sectional study |
2002-2003 |
Department of Microbiology, Basic Medical Sciences Institute, Jinnah Postgraduate Medical Centre, Karachi |
Burn wound infection |
52 |
190 |
41 |
N/A |
10 |
Clindamycin (70%), amikacin (90%), ciprofloxacin (100%), gentamicin (80%), clarithromycin (80%) |
Vancomycin (100%), chloramphenicol (100%) |
6 |
| Lee H.G., Korea, 2013 |
Cross-sectional study |
2007-2011 |
Burn intensive care unit |
Nosocomial infections/burn wound infection |
397 |
562 |
81 |
N/A |
78 |
N/A |
N/A |
8 |
| Singh N.P., India, 2017 |
Cross-sectional study |
2010-2014 |
Burn wards and intensive care unit |
Nosocomial infections/burn wound infection |
N/A |
762 |
N/A |
21 |
70 |
N/A |
N/A |
6 |
| Fransen J., Sweden, 2016 |
Cross-sectional study |
1994-2012 |
The Burn Center, Department of Hand, Plastic and Burn Surgery, University Hospital of Linko Ping |
Burn wound infection |
1570 |
4531 |
851 |
N/A |
15 |
N/A |
N/A |
8 |
